Peptide Ads: Why Google and Facebook Keep Saying No, and What Gets Approved?

Peptide ads are some of the hardest campaigns to get live on any major platform. I’ve watched founders with good products, clean lab reports, and real funding lose three ad accounts in a month, then decide paid media “just doesn’t work” for their category. It does work. It runs on different rules than selling sneakers or software seats, that’s all.

The peptide market has grown fast. Research peptides, cosmetic peptides, compounded GLP-1 programs sold through telehealth: they all want predictable customer acquisition. Meanwhile, the two biggest ad platforms treat the whole category with suspicion, because automated review systems can’t reliably tell a collagen serum from an unapproved injectable.

So here’s what I’ve learned about why peptide ads get rejected, and how brands get them approved anyway.

Why Peptide Ads Get Rejected So Often?

Google and Meta both run most policy review through machine learning. Their systems scan your ad copy, your landing page, your domain history, and sometimes your checkout. They’re hunting for signals tied to restricted categories: prescription drugs, unapproved substances, weight-loss claims, and anything that reads like a health promise.

Peptides trip several of those wires at once. Some compounds sit on Google’s list of unapproved substances outright. Others are perfectly legal to sell but get flagged because the word “peptide” appears near “injection” or “fat loss.” The reviewer, human or automated, sees that cluster and disapproves first. Questions come later, if at all.

Here’s the part most founders miss. The ad itself is rarely the whole problem. Both platforms crawl the destination URL, so one line in a product description promising “faster recovery” or “visible results in 14 days” can sink a perfectly clean ad.

How Google Peptide Ads Actually Get Approved

Google is the stricter of the two on substances, but it’s also more predictable. Its policies are published, the restricted categories are named, and disapprovals usually come with a reason you can act on.

What tends to work:

• Sell only what’s allowed in the country you’re targeting. Google enforces by geography, so a product restricted in the US may be fine in another market, and the reverse happens too.
• Keep claims off the page. No dosing, no outcomes, no before-and-after language. Product names, specs, purity documentation, and shipping details are much safer ground.
• Get certified where it applies. If you run a telehealth or pharmacy model, prescription GLP-1 programs being the obvious example, Google expects certification (usually through LegitScript) before you can advertise at all.
• Think about domain structure. An educational content site and a store that sells don’t always belong under one URL in the eyes of an ad reviewer.

Search is also where buying intent lives. Someone typing a specific compound name plus “buy” has already made a decision. That’s why well-built Google peptide ads often beat social on cost per acquisition, even with pricier clicks. The catch: one careless appeal or a repeated policy violation can get the entire account suspended, and Google suspensions are slow to reverse. Sometimes they never are.

What Makes Facebook Peptide Ads Different

Meta plays a different game. Its rules on drugs, health claims, and “personal attributes” are written more broadly, and enforcement feels less consistent. I’ve seen identical creative approved on one ad account and rejected on another the same afternoon.

Facebook and Instagram also bring a problem Google mostly doesn’t, which is the personal attributes policy. You can’t write copy that implies you know something about the viewer’s body or health. “Struggling with joint pain?” gets flagged. “How researchers study peptides in recovery” usually doesn’t.

That makes Facebook peptide ads a creative exercise more than a targeting one. Brands that do well on Meta tend to:

• Lead with education instead of product. Explainer videos, founder stories, and lab walkthroughs earn reach without tripping drug policies.
• Send cold traffic to content pages first, then retarget warm visitors toward product.
• Warm up new ad accounts slowly. A brand-new account spending $500 on day one in a sensitive category looks exactly like the behavior Meta’s risk systems were built to stop.
• Keep a backup Business Manager and a verified domain ready, so one ban doesn’t freeze everything.

Meta’s upside is scale and cheap awareness. Its downside is volatility. Plan for both.

The Landing Page Is Where Most Peptide Ads Fail

This deserves its own section. In the accounts I’ve audited, most disapprovals traced back to the landing page rather than the ad copy. Usual suspects:

• Health or performance claims buried in product descriptions
• Customer reviews that mention results, like “lost 12 pounds” or “my knee pain is gone”
• Dosing calculators or protocol guides living on the same domain as the checkout
• “Research use only” labels contradicted by gym photos and lifestyle imagery
• Thin business details: no address, no refund policy, no real contact page

Fix the page and half your policy headaches disappear. Leave it, and no amount of headline tweaking will save your peptide ads.

Building a Peptide Marketing Strategy That Survives a Ban

In the short term, the goal is getting campaigns approved. Over the long term, it’s making sure a single ban can’t take the business down with it.

In practice, that means running Google for high-intent search and Meta for awareness and retargeting rather than betting everything on one platform. It means owning first-party data, an email and SMS list you can reach no matter what an algorithm decides about your account. Document every disapproval, every appeal, and every change you make, because patterns show up quickly once they’re written down. And budget for a testing period.

A realistic timeline for a new peptide brand? Two to four weeks to reach stable approvals, then another month before the data is solid enough to scale. Founders who expect profitable peptide ads in week one usually burn through accounts trying to force it.

Should You Run Peptide Ads In-House or Get Help?

Honestly, it depends on how much you can afford to lose while learning. A small brand with time and a tolerance for a few banned accounts can figure this out alone. Plenty have.

Mistakes compound in this category, though. A suspended Google account can take weeks to resolve. A lost Meta pixel wipes out months of conversion data. If paid traffic is central to your growth plan, working with people who’ve already made those mistakes on someone else’s budget tends to be cheaper than making them yourself.

Final Thoughts on Peptide Ads

Peptide ads aren’t impossible. They’re unforgiving. Platform policies shift, enforcement is uneven, and automated reviewers lean toward “no.” The brands that get approved treat compliance as part of the marketing, build clean landing pages, and spread their risk across channels.

If your campaigns keep getting rejected, a better headline probably won’t fix it. A careful look at the whole funnel, from domain to checkout, usually will.

Not sure why your ads keep getting flagged? A second opinion from someone who reviews peptide accounts every week can save you a month of guesswork. Start by auditing your landing page against the checklist above, then decide whether you need outside help.

About the Author

The PeptAds team has spent more than a decade running paid campaigns for health, wellness, and peptide brands on Meta and Google. They focus on compliant creative, landing pages that pass review, and scaling ad accounts without putting them at risk.